The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
FaivreS., RaymondE., BoigeV.. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res.2001; 7: 43–50.
2.
DawsonL.K., JodrellD.I., BowmanA.. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer.2000; 36: 2353–2359.
3.
BorchmannP., SchnellR., KnippertzR.. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol.2001; 12: 661–667.
CamboniG., FayadL., TulpuleA.. A phase I/II trial of BBR-2778 (pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings).2004; 22(Suppl 14): 6590.
6.
FayadL., LiebmannJ., ModianoM.. Results of a Phase I/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL) [abstract]. Blood.2006; 108: 2758.
7.
BorchmannP., HerbrechtR., WilhelmM.. Results of a Phase II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma [abstract]. Blood.2006; 108: 529.
8.
BorchmannP., MorschhauserF., ParryA.. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica.2003; 88: 888–894.
9.
SantoroA., VoglovaJ., GabrailN.. Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings).2006; 24(Suppl 18S): 7578.
10.
KantarjianH., GilesF., WunderleL.. Nilotinib in imatinib-resistant CML and Philadelphia Chromosome-positive ALL. N Engl J Med.2006; 354: 2542–2551.
11.
WeisbergE., ManleyP.W., BreitensteinW.. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell.2005; 7: 129–141.
12.
WeisbergE., ManleyP., MestanJ., Cowan-Jacobs, RayA., GriffinJ.D.AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer.2006; 94: 1765–1769.
OttmannO., KantarjianH., LarsonR.. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) [abstract]. Blood.2006; 108: 1862.
15.
GilesF., Le CoutreP., BhallaK.. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib [abstract]. Blood.2006; 108: 2170.
16.
HochhausA., OttmannO., LauberS.. A phase II study of nilotinib, a novel inhibitor of c-Kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis [abstract]. Blood.2006; 108: 2703.
17.
KantarjianH.M., GattermannN., HochhausA.. A Phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) [abstract]. Blood.2006; 108: 2169.
18.
GilesF.J., LarsonR., Le CoutreP.. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings).2006; 24(Suppl 18S): 6536.
19.
Le CoutreP.D., OttmanO., GattermanN.. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings).2006; 24(Suppl 18S): 6531.
20.
KantarjianH.M., GattermannN., O'BrienS.G.. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings).2006; 24(Suppl 18S): 6534.
21.
JabbourE., CortesJ., GilesF.. Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP) [abstract]. Blood.2006; 108: 2172.
22.
Le CoutreP., BhallaK., GilesF.. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and –intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP) [abstract]. Blood.2006; 108: 165.
23.
JabbourE., KantarjianH., GilesF.. Treatment with nilotinib for patients with chronic myeloid leukemia (CML) who failed prior therapy with imatinib and dasatinib [abstract]. Blood.2006; 108: 2171.
24.
Le CoutreP., HochhausA., HeimD.. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosiniphilic syndrome (HES) [abstract]. Blood.2006; 108: 4912.
